FISIONERV ® IS EFFECTIVE IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN

Received 10th July, 2017 Received in revised form 3rd August, 2017 Accepted 11th September, 2017 Published online 28th October, 2017 The aim of the present study was to evaluate, in Neu P management, the effectiveness of “fisionerv®”, a gel for topical use. This study, conducted in the “Rehabilitation Unit of N. Melli ‘s Hospital, Brindisi, Italy”. was a doubleblind randomized controlled clinical trial, conducted over 8-week treatment on 58 outpatients affected by Neu P caused by lumbar sciatica or lumbar disk herniation and/or lumbar canal stenosis (31 subjects), or with carpal tunnel syndrome (27 subjects). Patients were randomly assigned to the following two groups : Group A: n = 29, received (fisionerv ® gel, 3 times /day) added to physiotherapy (forty minutes-daily session); Group B: n= 29 received a vehicle gel (placebo, 3 times /day) added to physiotherapy (forty minutes-daily session). Pain, burning, paraesthesiae and numbness were assessed by a visual analogue scale (VAS) at baseline and at the end of the treatment. Groups A showed a significant reduction in VAS and neuropathic symptoms after 8treatment weeks with a significant difference between the treatments (group A: VAS mean=1.89 (0.77); group B: VAS mean= 3.79 (1.20) (p < 0.001).

[1]  O. Lennon,et al.  Neuropathic pain prevalence following spinal cord injury: A systematic review and meta‐analysis , 2017, European journal of pain.

[2]  Jin Liu,et al.  Clinical practice guidelines for the management of neuropathic pain: a systematic review , 2015, BMC Anesthesiology.

[3]  M. Marrelli,et al.  Successful use of a topical mixture with ozolipoile in the treatment of actinic ulcers , 2015, Clinical, cosmetic and investigational dermatology.

[4]  C Kent Kwoh,et al.  Low back pain and other musculoskeletal pain comorbidities in individuals with symptomatic osteoarthritis of the knee: Data from the osteoarthritis initiative , 2010, Arthritis care & research.

[5]  Joshua S. Coren,et al.  Potential for Pregabalin Abuse or Diversion After Past Drug-Seeking Behavior , 2010, The Journal of the American Osteopathic Association.

[6]  G. Cruccu,et al.  EFNS guidelines on neuropathic pain assessment: revised 2009 , 2010, European journal of neurology.

[7]  R. Tashjian,et al.  Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. , 2009, Journal of shoulder and elbow surgery.

[8]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[9]  T. Graven-Nielsen,et al.  Fundamentals of muscle pain, referred pain, and deep tissue hyperalgesia , 2006, Scandinavian journal of rheumatology. Supplement.

[10]  B. Hoggart,et al.  Pain: a review of three commonly used pain rating scales. , 2005, Journal of clinical nursing.

[11]  Donald D. Price,et al.  A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales , 1994, Pain.